Orionis Biosciences

Executive Summary

Orionis Biosciences is a clinical-stage biotechnology company headquartered in Ghent, Belgium, focused on developing precision medicines for oncology. The company leverages three proprietary platforms—molecular glues, conditionally active cytokines, and multimodal cell engagers—to reprogram protein and immune cell interactions, enabling targeted tumor killing while reducing off-target toxicities. Founded in 2015, Orionis has advanced its lead programs into Phase 1 clinical trials. The company's novel approach to harnessing the body’s immune defenses through conditionally active biologics positions it as an innovative player in the immuno-oncology space. With a strong scientific foundation and a growing pipeline, Orionis aims to deliver next-generation cancer therapies that improve efficacy and safety profiles over existing treatments. As a private entity without disclosed funding or valuation, the company remains relatively under the radar; however, its platform versatility and clinical progress suggest significant potential in the precision medicine landscape.

Upcoming Catalysts (preview)

• H2 2026Initial Phase 1 data readout for lead molecular glue program60% success
• H1 2027IND filing for next-generation conditionally active cytokine75% success
• H2 2026Potential strategic partnership or licensing deal for multimodal cell engager platform40% success